JOURNAL ONKOLOGIE – STUDIE
Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC
Rekrutierend
NCT-Nummer:
NCT04362072
Studienbeginn:
Oktober 2020
Letztes Update:
29.07.2021
Wirkstoff:
Lorlatinib
Indikation (Clinical Trials):
Lymphoma
Geschlecht:
Alle
Altersgruppe:
Erwachsene (18+)
Phase:
Phase 4
Sponsor:
Pfizer
Collaborator:
-
Studienleiter
Study Director
Pfizer
Kontakt
Kontakt:
Phone: 1-800-718-1021
E-Mail: ClinicalTrials.gov_Inquiries@pfizer.com» Kontaktdaten anzeigen
Studienlocations
(3 von 38)
92868 Orange
United StatesRekrutierend» Google-Maps
30607 Athens
United StatesNoch nicht rekrutierend» Google-Maps
20900 Monza
ItalyNoch nicht rekrutierend» Google-Maps
20132 Milano
ItalyRekrutierend» Google-Maps
20900 Monza
ItalyNoch nicht rekrutierend» Google-Maps
33081 Aviano
ItalyRekrutierend» Google-Maps
43126 Parma
ItalyNoch nicht rekrutierend» Google-Maps
00152 Roma
ItalyRekrutierend» Google-Maps
10043 Orbassano
ItalyNoch nicht rekrutierend» Google-Maps
83100 Avellino
ItalyRekrutierend» Google-Maps
70124 Bari
ItalyNoch nicht rekrutierend» Google-Maps
20-064 Lublin
PolandNoch nicht rekrutierend» Google-Maps
20-091 Lublin
PolandNoch nicht rekrutierend» Google-Maps
20-504 Lublin
PolandNoch nicht rekrutierend» Google-Maps
70-382 Szczecin
PolandNoch nicht rekrutierend» Google-Maps
70-784 Szczecin
PolandNoch nicht rekrutierend» Google-Maps
71-064 Szczecin
PolandNoch nicht rekrutierend» Google-Maps
71-252 Szczecin
PolandNoch nicht rekrutierend» Google-Maps
02-781 Warszawa
PolandNoch nicht rekrutierend» Google-Maps
02-801 Warszawa
PolandNoch nicht rekrutierend» Google-Maps
28222 Majadahonda
SpainRekrutierend» Google-Maps
15006 A Coruña
SpainNoch nicht rekrutierend» Google-Maps
08025 Barcelona
SpainNoch nicht rekrutierend» Google-Maps
08029 Barcelona
SpainNoch nicht rekrutierend» Google-Maps
08035 Barcelona
SpainRekrutierend» Google-Maps
08041 Barcelona
SpainNoch nicht rekrutierend» Google-Maps
08908 L'Hospitalet de Llobregat
SpainRekrutierend» Google-Maps
28034 Madrid
SpainNoch nicht rekrutierend» Google-Maps
29010 Malaga
SpainRekrutierend» Google-Maps
29011 Malaga
SpainRekrutierend» Google-Maps
29016 Málaga
SpainRekrutierend» Google-Maps
29016 Málaga
SpainRekrutierend» Google-Maps
41013 Sevilla
SpainRekrutierend» Google-Maps
7000 Chur
SwitzerlandNoch nicht rekrutierend» Google-Maps
8400 Winterthur
SwitzerlandNoch nicht rekrutierend» Google-Maps
SE1 9RT London
United KingdomNoch nicht rekrutierend» Google-Maps
M13 9WL Manchester
United KingdomRekrutierend» Google-Maps
M20 4BX Manchester
United KingdomRekrutierend» Google-Maps
Studien-Informationen
Brief Summary:A Phase 4 study to assess Overall and Intracranial Response Rate of single-agent lorlatinib
in participants with advanced ALK-positive NSCLC whose disease has progressed on alectinib or
ceritinib as the first ALK tyrosine kinase inhibitor (TKI)therapy.
Ein-/Ausschlusskriterien
Inclusion Criteria:- Participants must have evidence of histologically or cytologically confirmed diagnosis
of metastatic NSCLC (Stage IV, American Joint Committee on Cancer [AJCC] v7.0) that
carries an ALK rearrangement, as determined by the Food and Drug Administration (FDA)
approved fluorescence in situ hybridization (FISH) assay (Abbott Molecular Inc) or by
Immunohistochemistry (IHC) (Ventana Inc).
- Disease Status Requirements: disease progression after alectinib or ceritinib as first
line therapy (the study will limit enrollment of participants with best response of
progression or indeterminate on prior alectinib to 8 participants). Participants may
have had prior chemotherapy, but only if before starting treatment with alectinib or
ceritinib.
- Tumor Requirements: All Participants must have at least one measurable target
extracranial lesion according to RECIST v1.1. Participants with asymptomatic CNS
metastases (including participants controlled with stable or decreasing steroid use
within the last 2 weeks prior to study entry) will be eligible. Participants who have
leptomeningeal disease (LM) or carcinomatous meningitis (CM) will be eligible if the
LM/CM is visualized on magnetic resonance imaging (MRI) or if documented baseline
cerebral spinal fluid (CSF) positive cytology is available.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.
- Adequate bone marrow functioning, pancreatic function, renal function and liver
function
- Acute effects of any prior therapy resolved to baseline severity or to CTCAE Grade ≤1
except for adverse events (AEs) that in the investigator' judgment do not constitute a
safety risk for the participant.
- Systemic anti-cancer therapy with alectinib or ceritinib discontinued within a minimum
of 5 half-lives prior to first dose of lorlatinib on the study (unless clinically
meaningful tumor flare per discretion of the investigator, in which discussion with
the sponsor is warranted).
- Male participants are eligible to participate if they agree to use proper
contraception during the intervention period and for at least 98 days after the last
dose of study intervention
- Female participants are eligible to participate if they are not pregnant or
breastfeeding, and agree to use proper contraception during the intervention period
and for at least 35 days after the last dose of study intervention.
- Capable of giving signed informed consent and willingness and ability to comply with
the study scheduled visits and other procedures.
Exclusion criteria:
- Prior ALK TKI treatment or anti-cancer treatment other than first line alectinib or
ceritinib.
- Spinal cord compression unless the participant has good pain control attained through
therapy, and there is stabilization or recovery of neurological function for the 4
weeks prior to randomization.
- Gastrointestinal abnormalities, including inability to take oral medication;
requirement for intravenous alimentation; prior surgical procedures affecting
absorption including total gastric resection or lap band; active inflammatory
gastrointestinal disease, chronic diarrhea, symptomatic diverticular disease;
treatment for active peptic ulcer disease in the past 6 months; malabsorption
syndromes.
- Active and clinically significant bacterial, fungal, or viral infection including
hepatitis B virus (HBV) or hepatitis C virus (HCV), known human immunodeficiency virus
(HIV), or acquired immunodeficiency syndrome (AIDS) related illness.
- Clinically significant vascular (both arterial and venous) and non-vascular cardiac
conditions, (active or within 3 months prior to enrollment)
- Participants presenting with abnormal Left Ventricular Ejection Fraction (LVEF) by
echocardiogram or Multi-Gated Acquisition Scan according to institutional lower
limits.
- Participants with predisposing characteristics for acute pancreatitis according to
investigator judgment
- History or known presence of interstitial fibrosis, interstitial lung disease,
pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative
bronchiolitis, and pulmonary fibrosis.
- Other severe acute or chronic medical or psychiatric condition, including recent
(within the past year) or active suicidal ideation or behavior, or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the participant
inappropriate for entry into this study.
- Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in
situ cervical cancer, papillary thyroid cancer, ductal carcinoma in situ (DCIS) of the
breast or localized and presumed cured prostate cancer) within the last 3 years prior
to randomization.
- Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study
entry. Palliative radiation must have been completed at least 48 hours prior to study
entry. Stereotactic or small field brain irradiation must have completed at least 2
weeks prior to study entry. Whole brain radiation must have completed at least 4 weeks
prior to study entry.
- Prior irradiation to >25% of the bone marrow.
- Concurrent use of any of the following food or drugs within 12 days prior to the first
dose of lorlatinib: known strong CYP3A inducers, known strong CYP3A inhibitors, known
CYP3A substrates with narrow therapeutic index, known permeability glycoprotein (P-gp)
substrates with a narrow therapeutic index
- Major surgery within 4 weeks prior to enrollment.
- Known prior or suspected severe hypersensitivity to study interventions or any
component in their formulations.
- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
Pfizer employees, including their family members, directly involved in the conduct of
the study.
Studien-Rationale
Primary outcome:1. Percentage of Patients With Overall Objective Response (OR) based on independent central review (ICR) (Time Frame - every 6 weeks up to 3.5 years):
OR (Objective Response) based on ICR assessment is defined as complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.
Secondary outcome:
1. Percentage of Patients With Overall OR based on Investigator (INV) (Time Frame - every 6 weeks up to 3.5 years):
OR based on INV assessment is defined as CR or PR according to RECIST v1.1. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.
2. Percentage of Patients With Intra-Cranial Objective Response (IC-OR) based on ICR/derived INV (Time Frame - every 6 weeks up to 3.5 years):
IC-OR is defined as Intra-Cranial complete response (IC-CR) or partial response (IC-PR) according to RECIST v1.1. Both IC-CR and IC-PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.
3. Time to Response (TTR) based on ICR/derived INV (Time Frame - every 6 weeks up to 3.5 years):
TTR is defined, for participants with a confirmed OR, as the time from the date of first dose to the first documentation of objective response (CR or PR) which is subsequently confirmed.
4. Time to Intra-Cranial Response (IC-TTR) based on ICR/derived investigator (Time Frame - every 6 weeks up to 3.5 years):
IC-TTR is defined, for participants with a confirmed intra-cranial objective response, as the time from the date of first dose to the first documentation of objective intra-cranial response (CR or PR) which is subsequently confirmed.
5. Duration of Response (DoR) based on ICR/ derived investigator (Time Frame - every 6 weeks up to 3.5 years):
DoR is defined, for participants with a confirmed objective response, as the time from first documentation of objective response (CR or PR whichever is earlier) to the date of first documentation of PD or death due to any cause, whichever occurs first
6. Duration of Intra-Cranial Response (IC-DoR) based on ICR/ derived INV (Time Frame - every 6 weeks up to 3.5 years):
IC-DoR is defined, for participants with a confirmed objective intra-cranial response, as the time from first documentation of objective intra-cranial response (CR or PR whichever is earlier) to the date of first documentation of PD in brain or death due to any cause, whichever occurs first.
7. Progression Free Survival (PFS) based on ICR/derived INV (Time Frame - every 6 weeks up to 3.5 years):
PFS is defined as the time from date of first dose to the date of the first documentation of PD (per RECIST v1.1) or death due to any cause, whichever occurs first.
8. Time To Progression (TTP) based on ICR/derived INV (Time Frame - every 6 weeks up to 3.5 years):
TTP is defined as the time from date of first dose to the date of the first documentation of PD (per RECIST v1.1).
9. Adverse Event (AE) as graded by NCI CTCAE (v 4.03) (Time Frame - From study start up to 3.5 years):
Frequency of patients experiencing treatment-emergent AEs (TEAEs)
Geprüfte Regime
- Lorlatinib:
25 milligram (mg) tablet
Quelle: ClinicalTrials.gov
Das könnte Sie auch interessieren
